Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 27.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 70,005 shares of the biopharmaceutical company’s stock after acquiring an additional 15,032 shares during the period. Hsbc Holdings PLC’s holdings in Akebia Therapeutics were worth $131,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. SRS Capital Advisors Inc. acquired a new stake in Akebia Therapeutics during the fourth quarter worth about $26,000. PDS Planning Inc purchased a new stake in shares of Akebia Therapeutics in the 4th quarter valued at approximately $28,000. Mariner LLC purchased a new stake in shares of Akebia Therapeutics in the 4th quarter valued at approximately $28,000. Cibc World Markets Corp acquired a new stake in shares of Akebia Therapeutics during the 4th quarter worth approximately $37,000. Finally, Wealth Effects LLC raised its position in shares of Akebia Therapeutics by 18.5% during the 4th quarter. Wealth Effects LLC now owns 32,000 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 5,000 shares during the period. Institutional investors and hedge funds own 33.92% of the company’s stock.

Akebia Therapeutics Trading Down 2.7%

Shares of NASDAQ AKBA opened at $2.55 on Monday. The stock has a market capitalization of $667.55 million, a PE ratio of -11.09 and a beta of 0.88. Akebia Therapeutics, Inc. has a twelve month low of $0.80 and a twelve month high of $2.90. The stock has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $1.99.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.06. The firm had revenue of $57.34 million for the quarter, compared to analysts’ expectations of $44.88 million. On average, equities analysts predict that Akebia Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AKBA shares. StockNews.com upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 3rd. Leerink Partnrs upgraded Akebia Therapeutics to a “strong-buy” rating in a report on Monday, April 28th. Piper Sandler raised their price objective on Akebia Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research report on Friday, April 4th. Finally, Jefferies Financial Group began coverage on shares of Akebia Therapeutics in a research report on Tuesday, April 1st. They set a “buy” rating and a $6.00 price target for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $6.63.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.